medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2013-11-34-37medsovet-1143Research ArticleБронхиальная астмаBronchial asthmaМелкие воздухоносные пути при бронхиальной астме – возможности терапииSmall airways in asthma: treatment optionsЗыковК. А.ZykovK. A.noemail@neicon.ruМГМСУРоссияMSUMSRussian Federation2013301220130113437Copyright © Зыков К.А., 20132013Зыков К.А.Zykov K.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1143

Согласно современным представлениям, бронхиальная астма (БА) определяется как хроническое воспалительное заболевание воздухоносных путей, в котором играют роль многие клетки и клеточные элементы. Хроническое воспаление ассоциировано с гиперреактивностью воздухоносных путей, что ведет к повторяющимся эпизодам хрипов, одышки, стеснения в груди, кашля (особенно по ночам и ранним утром). Эти эпизоды обычно ассоциированы с распространенной, но вариабельной обструкцией воздухоносных путей, которая часто обратима спонтанно или под влиянием терапии [1].

According to the modern idea, bronchial asthma (BA) is a chronic inflammatory disease of the airways in which many cells and cellular elements play a role. Chronic inflammation is associated with airway hyperresponsiveness that leads to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, (especially at night or in the early morning). These episodes are usually associated with widespread, but variable, airflow obstruction within the lung that is often reversible either spontaneously or with treatment [1].

бронхиальная астмамелкие воздухоносные путиультрамелкодисперсный аэрозольhmasmall airwaysultra-fine aerosolReferencesGlobal Initiative for Asthma (GINA). Global strategy for asthma management and prevention (updated 2013). www.ginasthma.comGlobal Initiative for Asthma (GINA). Global strategy for asthma management and prevention (updated 2013). www.ginasthma.comWorld Health Organization Asthma fact sheet. Date last accessed: September 2011. Date last updated: May 2011. www.who.int/ mediacentre/factsheets/fs307/en/index.htmlWorld Health Organization Asthma fact sheet. Date last accessed: September 2011. Date last updated: May 2011. www.who.int/ mediacentre/factsheets/fs307/en/index.htmlMasoli M., Fabian D., Holt S. et al. The global burden of asthma: executive summary of the GINA Dissemination Committee Report // Allergy. 2004. №59. Р. 469–478.Masoli M., Fabian D., Holt S. et al. The global burden of asthma: executive summary of the GINA Dissemination Committee Report // Allergy. 2004. №59. Р. 469–478.Colice G., Martin R.J., Israel E. et al. Asthma outcomes and costs of therapy with extrafine beclomethasone and fluticasone // J. Allergy Clin. Immunol.. 2013. Jul. №132(1). Р. 45–54.Colice G., Martin R.J., Israel E. et al. Asthma outcomes and costs of therapy with extrafine beclomethasone and fluticasone // J. Allergy Clin. Immunol.. 2013. Jul. №132(1). Р. 45–54.Scichilone N., Spatafora M., Battaglia S. et al. Lung penetration and patient adherence considerations in the management of asthma: role of extra-fine formulations // J. Asthma Allergy. 2013. №6. Р. 11-21.Scichilone N., Spatafora M., Battaglia S. et al. Lung penetration and patient adherence considerations in the management of asthma: role of extra-fine formulations // J. Asthma Allergy. 2013. №6. Р. 11-21.Demoly P., Annunziata K., Gubba E., Adamek L. Repeated cross-sectional survey of patient- reported asthma control in Europe in the past 5 years // Eur. Respir. Rev. 2012. №21. 123. Р. 66–74.Demoly P., Annunziata K., Gubba E., Adamek L. Repeated cross-sectional survey of patient- reported asthma control in Europe in the past 5 years // Eur. Respir. Rev. 2012. №21. 123. Р. 66–74.Soriano J.B., Rabe K.F., Vermeire P.A. Predictors of poor asthma control in European adults // J. Asthma. 2003. №40. Р. 803–813.Soriano J.B., Rabe K.F., Vermeire P.A. Predictors of poor asthma control in European adults // J. Asthma. 2003. №40. Р. 803–813.Piccinno A., Poli G., Monno R. et al. (2012) Extrafine Beclometasone Dipropionate and Formoterol in Single and Separate Inhalers // Clinic Pharmacol. Biopharm. 1:102. doi:10.4172/2167-065X.1000102Piccinno A., Poli G., Monno R. et al. (2012) Extrafine Beclometasone Dipropionate and Formoterol in Single and Separate Inhalers // Clinic Pharmacol. Biopharm. 1:102. doi:10.4172/2167-065X.1000102Barnes P.J. Similarities and differences in inflammatory mechanisms of asthma and COPD // Breathe. 2011. №7. Р. 229–238.Barnes P.J. Similarities and differences in inflammatory mechanisms of asthma and COPD // Breathe. 2011. №7. Р. 229–238.Laube B., Janssens H., De Jongh F. et al. What the pulmonary specialist should know about the new inhalation therapies // European Respiratory Journal. 2011. Vol. 37. №6. Р. 1308–1331.Laube B., Janssens H., De Jongh F. et al. What the pulmonary specialist should know about the new inhalation therapies // European Respiratory Journal. 2011. Vol. 37. №6. Р. 1308–1331.Dolovich M., Ahrens R., Hessetal D. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology // Chest. 2005. Vol. 127. №1. Р. 335–371.Dolovich M., Ahrens R., Hessetal D. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology // Chest. 2005. Vol. 127. №1. Р. 335–371.Sanchis J., Corrigan C., Levy M., Viejo J. Inhaler devices—from theory to practice // Respiratory Medicine. 2013. Vol. 107. №4. Р. 495–502.Sanchis J., Corrigan C., Levy M., Viejo J. Inhaler devices—from theory to practice // Respiratory Medicine. 2013. Vol. 107. №4. Р. 495–502.Haldar P., Pavord I.D., Shaw D.E. et al. Cluster analysis and clinical asthma phenotypes // Am. J. Respir. Crit. Care Med. 2008. Aug. 1. №178(3). Р. 218–224.Haldar P., Pavord I.D., Shaw D.E. et al. Cluster analysis and clinical asthma phenotypes // Am. J. Respir. Crit. Care Med. 2008. Aug. 1. №178(3). Р. 218–224.Ambrosino N., Paggiaro P. The management of asthma and chronic obstructive pulmonary disease: current status and future perspectives // Expert Rev. Respir. Med. 2012. Feb. №6(1). Р. 117–127.Ambrosino N., Paggiaro P. The management of asthma and chronic obstructive pulmonary disease: current status and future perspectives // Expert Rev. Respir. Med. 2012. Feb. №6(1). Р. 117–127.Usmani O.S., Biddiscombe M.F., Barnes P.J. Regional lung deposition and bronchodilator response as a function of beta2-agonistUsmani O.S., Biddiscombe M.F., Barnes P.J. Regional lung deposition and bronchodilator response as a function of beta2-agonistBateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004;170(8):836-44Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004;170(8):836-44LazarusSC,BousheyHA,FahyJV,ChinchilliVM,Lemanske RF, Jr., Sorkness CA, et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001;285(20):2583-93LazarusSC,BousheyHA,FahyJV,ChinchilliVM,Lemanske RF, Jr., Sorkness CA, et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001;285(20):2583-93Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O’Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337(20):1405-11Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O’Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337(20):1405-11Takeda T, Oga T, Niimi A, et al. Relationship between small airway function and health status, dyspnea, and disease control in asthma. Respiration. 2010;80:120–126Takeda T, Oga T, Niimi A, et al. Relationship between small airway function and health status, dyspnea, and disease control in asthma. Respiration. 2010;80:120–126Martin RJ. Therapeutic significance of distal airway inflammation in asthma. J Allergy Clin Immunol. 2002;109(Suppl 2):S447–S460.Martin RJ. Therapeutic significance of distal airway inflammation in asthma. J Allergy Clin Immunol. 2002;109(Suppl 2):S447–S460.Contoli M, Bousquet J, Fabbri LM, et al. The small airways and distal lung compartment in asthma and COPD: a time for reappraisal. Allergy. 2010;65(2):141–151Contoli M, Bousquet J, Fabbri LM, et al. The small airways and distal lung compartment in asthma and COPD: a time for reappraisal. Allergy. 2010;65(2):141–151Virchow JC. [Asthma—a small airway disease: concepts and evidence]. Pneumologie 2009;63 Suppl 2:S96-101Virchow JC. [Asthma—a small airway disease: concepts and evidence]. Pneumologie 2009;63 Suppl 2:S96-101Barnes PJ Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids. Eur Respir J 2002, 19: 182-191Barnes PJ Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids. Eur Respir J 2002, 19: 182-191Mak JC, Nishikawa M, Barnes PJ Glucocorticosteroids increase β2- adrenergic receptor transcription in human lung. Am J Physiol, 1995, 268: L41-L46.Mak JC, Nishikawa M, Barnes PJ Glucocorticosteroids increase β2- adrenergic receptor transcription in human lung. Am J Physiol, 1995, 268: L41-L46.Tanaka H, Hashimoto M, Fujii M Reduction of Eosinophils in Small Airways by Inhaled Steroids is Insufficient in Patients with Adult Asthma. Allergology International. 2006;55:305-309Tanaka H, Hashimoto M, Fujii M Reduction of Eosinophils in Small Airways by Inhaled Steroids is Insufficient in Patients with Adult Asthma. Allergology International. 2006;55:305-309Hauber HP, Gotfried M, Newman K et al. Effect of HFA- flunisolide on peripheral lung inflammation in asthma. J. Allergy Clin. Immunol. 2003;112:58-63Hauber HP, Gotfried M, Newman K et al. Effect of HFA- flunisolide on peripheral lung inflammation in asthma. J. Allergy Clin. Immunol. 2003;112:58-63Busse WW, Brazinsky S, Jacobson K, Stricker W, Schmitt K, et al. (1999) Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 104: 1215-22.Busse WW, Brazinsky S, Jacobson K, Stricker W, Schmitt K, et al. (1999) Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 104: 1215-22.Rigamonti E, Kottakis I, Pelc M, Grzelewska Rzymowska I, Feschenko Y (2006) Comparison of a new extrafine beclometasone dipropionate HFA 134a-formulated pMDI with a standard BDP CFC pMDI in adults with moderate persistent asthma. Eur Respir J 28: 206-207.Rigamonti E, Kottakis I, Pelc M, Grzelewska Rzymowska I, Feschenko Y (2006) Comparison of a new extrafine beclometasone dipropionate HFA 134a-formulated pMDI with a standard BDP CFC pMDI in adults with moderate persistent asthma. Eur Respir J 28: 206-207.Bousquet J, Poli G, Acerbi D, Monno R, Ramael S, et al. (2009) Systemic exposure and implications for lung deposition with an extrafine Hudrofluroalkane beclometasone dipropionate/formoterol fixed combination. Clin Pharmacokinet 48: 347-358.Bousquet J, Poli G, Acerbi D, Monno R, Ramael S, et al. (2009) Systemic exposure and implications for lung deposition with an extrafine Hudrofluroalkane beclometasone dipropionate/formoterol fixed combination. Clin Pharmacokinet 48: 347-358.Papi A, Paggiaro P, Nicolini G, Vignola AM, Fabbri LM. Beclomethasone/ formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy. 2007;62(10):1182–1188Papi A, Paggiaro P, Nicolini G, Vignola AM, Fabbri LM. Beclomethasone/ formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy. 2007;62(10):1182–1188Papi A, Paggiaro PL, Nicolini G et al. Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. Eur Respir J. 2007 Apr;29(4):682-9Papi A, Paggiaro PL, Nicolini G et al. Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. Eur Respir J. 2007 Apr;29(4):682-9

The authors declare that there are no conflicts of interest present.